141 related articles for article (PubMed ID: 18481916)
1. Importance and prospects for design of selective muscarinic agonists.
Jakubík J; Michal P; Machová E; Dolezal V
Physiol Res; 2008; 57 Suppl 3():S39-S47. PubMed ID: 18481916
[TBL] [Abstract][Full Text] [Related]
2. Classical and atypical agonists activate M1 muscarinic acetylcholine receptors through common mechanisms.
Randáková A; Dolejší E; Rudajev V; Zimčík P; Doležal V; El-Fakahany EE; Jakubík J
Pharmacol Res; 2015 Jul; 97():27-39. PubMed ID: 25882246
[TBL] [Abstract][Full Text] [Related]
3. Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors.
Jakubík J; El-Fakahany EE; Dolezal V
Mol Pharmacol; 2006 Aug; 70(2):656-66. PubMed ID: 16675658
[TBL] [Abstract][Full Text] [Related]
4. Long-term changes in the muscarinic M1 receptor induced by instantaneous formation of wash-resistant xanomeline-receptor complex.
De Lorme KC; Grant MK; Noetzel MJ; Polson SB; El-Fakahany EE
J Pharmacol Exp Ther; 2007 Dec; 323(3):868-76. PubMed ID: 17855477
[TBL] [Abstract][Full Text] [Related]
5. Striatal, Hippocampal, and Cortical Networks Are Differentially Responsive to the M4- and M1-Muscarinic Acetylcholine Receptor Mediated Effects of Xanomeline.
Thorn CA; Moon J; Bourbonais CA; Harms J; Edgerton JR; Stark E; Steyn SJ; Butter CR; Lazzaro JT; O'Connor RE; Popiolek M
ACS Chem Neurosci; 2019 Mar; 10(3):1753-1764. PubMed ID: 30480428
[TBL] [Abstract][Full Text] [Related]
6. Effects of the M1 agonist xanomeline on processing of human beta-amyloid precursor protein (FAD, Swedish mutant) transfected into Chinese hamster ovary-m1 cells.
DeLapp N; Wu S; Belagaje R; Johnstone E; Little S; Shannon H; Bymaster F; Calligaro D; Mitch C; Whitesitt C; Ward J; Sheardown M; Fink-Jensen A; Jeppesen L; Thomsen C; Sauerberg P
Biochem Biophys Res Commun; 1998 Mar; 244(1):156-60. PubMed ID: 9514902
[TBL] [Abstract][Full Text] [Related]
7. Design and development of selective muscarinic agonists for the treatment of Alzheimer's disease: characterization of tetrahydropyrimidine derivatives and development of new approaches for improved affinity and selectivity for M1 receptors.
Messer WS; Rajeswaran WG; Cao Y; Zhang HJ; el-Assadi AA; Dockery C; Liske J; O'Brien J; Williams FE; Huang XP; Wroblewski ME; Nagy PI; Peseckis SM
Pharm Acta Helv; 2000 Mar; 74(2-3):135-40. PubMed ID: 10812950
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological evaluation of the long-term effects of xanomeline on the M(1) muscarinic acetylcholine receptor.
Grant MK; Noetzel MJ; De Lorme KC; Jakubík J; Doležal V; El-Fakahany EE
PLoS One; 2010 Dec; 5(12):e15722. PubMed ID: 21203415
[TBL] [Abstract][Full Text] [Related]
9. Long-term activation upon brief exposure to xanomleline is unique to M1 and M4 subtypes of muscarinic acetylcholine receptors.
Šantrůčková E; Doležal V; El-Fakahany EE; Jakubík J
PLoS One; 2014; 9(2):e88910. PubMed ID: 24558448
[TBL] [Abstract][Full Text] [Related]
10. Novel persistent activation of muscarinic M1 receptors by xanomeline.
Christopoulos A; El-Fakahany EE
Eur J Pharmacol; 1997 Sep; 334(1):R3-4. PubMed ID: 9346340
[TBL] [Abstract][Full Text] [Related]
11. The M1/M4 preferring agonist xanomeline is analgesic in rodent models of chronic inflammatory and neuropathic pain via central site of action.
Martino G; Puma C; Yu XH; Gilbert AK; Coupal M; Markoglou N; McIntosh FS; Perkins MN; Laird JMA
Pain; 2011 Dec; 152(12):2852-2860. PubMed ID: 22018972
[TBL] [Abstract][Full Text] [Related]
12. The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-m1 cells.
Eckols K; Bymaster FP; Mitch CH; Shannon HE; Ward JS; DeLapp NW
Life Sci; 1995; 57(12):1183-90. PubMed ID: 7674807
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands.
Davis CN; Bradley SR; Schiffer HH; Friberg M; Koch K; Tolf BR; Bonhaus DW; Lameh J
BMC Pharmacol; 2009 Dec; 9():14. PubMed ID: 19951444
[TBL] [Abstract][Full Text] [Related]
14. Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor.
Grant MK; El-Fakahany EE
J Pharmacol Exp Ther; 2005 Oct; 315(1):313-9. PubMed ID: 16002459
[TBL] [Abstract][Full Text] [Related]
15. Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease.
Melancon BJ; Tarr JC; Panarese JD; Wood MR; Lindsley CW
Drug Discov Today; 2013 Dec; 18(23-24):1185-99. PubMed ID: 24051397
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of LY593093, an M1 muscarinic acetylcholine receptor-selective partial orthosteric agonist.
Watt ML; Schober DA; Hitchcock S; Liu B; Chesterfield AK; McKinzie D; Felder CC
J Pharmacol Exp Ther; 2011 Aug; 338(2):622-32. PubMed ID: 21558436
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological analysis of the novel mode of interaction between xanomeline and the M1 muscarinic acetylcholine receptor.
Christopoulos A; Parsons AM; El-Fakahany EE
J Pharmacol Exp Ther; 1999 Jun; 289(3):1220-8. PubMed ID: 10336509
[TBL] [Abstract][Full Text] [Related]
18. In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M
Mandai T; Kasahara M; Kurimoto E; Tanaka M; Suzuki M; Nakatani A; Kimura H
Neuroscience; 2019 Aug; 414():60-76. PubMed ID: 31299348
[TBL] [Abstract][Full Text] [Related]
19. Role of receptor protein and membrane lipids in xanomeline wash-resistant binding to muscarinic M1 receptors.
Jakubík J; Tucek S; El-Fakahany EE
J Pharmacol Exp Ther; 2004 Jan; 308(1):105-10. PubMed ID: 14569060
[TBL] [Abstract][Full Text] [Related]
20. Effects of muscarinic M
Stoll K; Hart R; Lindsley CW; Thomsen M
Psychopharmacology (Berl); 2018 Mar; 235(3):815-827. PubMed ID: 29250738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
